Losartan Potassium Tablet, Film Coated
Product Images NDC 71610-465

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71610-465). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 100 mg (71610 0465 30)

Label for Losartan Potassium USP 100 mg film-coated tablets, containing 30 tablets per container. The label includes storage instructions to keep between 20-25 degrees Celsius and dispense in a tight, light-resistant container. It is manufactured by Ascent Pharmaceuticals, Inc. and labeled by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The product is marked as prescription only (RX Only).*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure-1 (Losartan Fig1)

A line graph comparing the percentage of patients with primary endpoints over study months between Losartan Potassium and Atenolol. The x-axis represents study months (0 to 66), and the y-axis shows the percentage of patients (0 to 16%). The graph indicates Adjusted Risk Reduction of 13% with Losartan Potassium versus Atenolol, with a p-value of 0.021.*

FDA Label Image

Figure-2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 study months between atenolol (dotted line) and losartan potassium (solid line). The graph indicates an adjusted risk reduction of 25% with losartan potassium, with statistical significance p=0.001.*

FDA Label Image

Figure-3 (Losartan Fig3)

A figure presenting primary endpoint event rates within demographic subgroups for Losartan Potassium and Atenolol in a study population of 9,193 patients. It shows event rates (%) for primary composite outcomes and stroke (fatal/non-fatal) with hazard ratios and 95% confidence intervals, segmented by age, gender, race, ischemic heart status, diabetes, and cardiovascular disease history. The graph indicates relative risk comparison between Losartan Potassium and Atenolol treatments.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The graph shows risk reduction of 16.1% with a p-value of 0.022, illustrating a divergence in event rates between the two groups over time.*

FDA Label Image

Structure (Losartan Struct)

Chemical structure of losartan potassium, showing its molecular arrangement with potassium ion (K+), characteristic ring systems, and functional groups.*

FDA Label Image

Table-2 (Losartan Table2)

A data table presenting pharmacokinetic parameters in hypertensive adults and children aged 6-16 following multiple dosing. It compares values for parent compound and active metabolite after different dosing regimens over 7 days, including AUC0-24, Cmax, T1/2, Tpeak, and clearance for each group.*

FDA Label Image

Table-3 (Losartan Table3)

Data table presenting the incidence of primary endpoint events comparing Losartan Potassium and Atenolol in a clinical study. It includes rates, risk reduction percentages, 95% confidence intervals, and p-values for composite endpoints, stroke, myocardial infarction, and cardiovascular mortality, with notes on rate adjustments and definitions of event categories.*

FDA Label Image

Table-4 (Losartan Table4)

A data table titled 'Table 4: Incidence of Primary Endpoint Events' comparing incidence, risk reduction, 95% confidence intervals, and p-values of primary composite endpoints and adverse events including doubling of serum creatinine, ESRD, and death between losartan and placebo groups.*

FDA Label Image

Table-5 (Losartan Table5)

A data table titled 'Table 5: Efficacy Outcomes within Demographic Subgroups' showing comparative event rates, hazard ratios, and confidence intervals for Losartan Potassium versus placebo across different patient demographics (age, gender, race). The table includes efficacy outcomes for the Primary Composite Endpoint and ESRD (End-Stage Renal Disease) event rates in patients.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.